The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4th Novel Conjugates Summit gives you an insider’s perspective on what’s working, what’s next, and what’s gaining traction across the industry.
Inside, you’ll uncover:
- Cutting-edge payload and format strategies, including peptide-drug conjugates, antibody-oligonucleotide conjugates, and bispecific ADCs
- Insights into design, translation, and development that are opening doors to next-gen conjugates for broader patient reach
- Deal trends, pipeline updates, and investment signals shaping the future of the conjugate landscape
Access your free copy to explore the innovations driving the next wave of targeted therapies.
About Hanson Wade Group - 5th Novel Conjugates Summit 2026
Spotlighting Innovation in Novel Targeting Formats & Payloads to Enhance Delivery, Overcome Payload Resistance and Expand Therapeutic Reach
Novel conjugates have become one of the most competitive and rapidly evolving areas in the precision oncology landscape. Companies are looking beyond traditional ADCs towards novel mechanism of action payloads and differentiated targeting formats for overcoming drug resistance, improved therapeutic windows and to make an impact in cancers which don’t respond to traditional ADCs, as well as the exploration of non-oncology indications.
The 5th Novel Conjugates Summit is the industry’s only dedicated meeting for an insider view into which novel approaches are currently being explored, what benefit each approach has and the directions the space is heading.
Attendees gain valuable competitive insight into emerging technologies, early data, and the rationale behind each approach, from established pharma leaders to the newest biotech entrants. Whether your goal is to benchmark your pipeline, explore partnership opportunities, or stay ahead of fast-moving design trends, this summit offers a front-row seat to the next wave of conjugate innovation.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.